Creative Biolabs, a biotechnology research service provider, has expanded its complement assay service portfolio to support the development of next-generation complement therapeutics. The company now offers enhanced capabilities for evaluating complement pathway activity, therapeutic mechanisms, and candidate performance during preclinical development, addressing the growing demand for specialized functional assays in complement-targeted drug discovery.
Researchers developing complement therapeutics often encounter challenges due to the complexity of biological pathways, the need for assay optimization, and the requirement for reproducible data to guide development decisions. Without robust evaluation methods, identifying promising candidates and understanding their biological effects can become time-consuming and resource-intensive. Creative Biolabs' expanded services aim to mitigate these challenges by providing customizable complement assay solutions for research programs spanning early discovery and preclinical evaluation.
Among the new offerings is the C3b deposition assay, which measures C3b deposition, a critical marker in the complement cascade. This assay supports the characterization of complement-targeting antibodies, proteins, and other therapeutic candidates by providing quantitative data on pathway regulation and biological activity. The company also offers a hemolytic inhibition assay to evaluate the ability of test candidates to inhibit complement-mediated cell lysis, enabling comparisons of inhibitory activity under defined experimental conditions.
Additionally, Creative Biolabs provides individual components activity tests for detailed analysis of specific complement proteins. These services allow researchers to evaluate individual complement components, generating data for mechanistic studies, pathway investigations, and the development of complement-modulating strategies. With expertise in biotechnology research and assay development, Creative Biolabs delivers flexible and reliable testing solutions that help reduce research complexity and improve development efficiency.
The expansion of Creative Biolabs' complement assay services reflects the company's commitment to supporting complement-focused research. By combining scientific expertise with customized assay solutions, the company aims to help researchers generate actionable data for therapeutic candidate characterization and optimization. This development is significant for pharmaceutical and biotechnology companies working on complement-targeted therapies, as it provides them with essential tools to advance their drug discovery programs.
For more information about Creative Biolabs' complement assay services, visit https://www.creative-biolabs.com/complement-therapeutics/.
